Catalent Expands its Advanced Aseptic, Glass-Free Injectable Platform with New Advasep Lock Delivery Technology
![](/46/pdcnewsitem/03/44/11/rX6ZxJFwSgS86gO.png)
Catalent has announced the launch of Advasept Lock, a stopper-less, glass- and needle-free vial for the safe and efficient delivery of injectable medications. Easily opened, Advasept Lock attaches to a luer syringe, combining a safe, convenient and functional container closure with the security of an advanced aseptic filling solution.
Like the rest of Catalent’s advanced, aseptic Advasept technology family, Advaesept Lock addresses many sterile manufacturing challenges by automating the container formation and filling of the drug product into a glass-free container closure, eliminating glass particulates and delamination issues, and drastically reducing the risk of foreign particle and microbial contamination. Minimizing the risk of these types of manufacturing issues has the potential to improve the reliability of supply that targets the root cause of many generic injectable drug shortage issues.
The technology also offers safety advantages, as no needle is required for the withdrawal of the vial contents, while the design avoids the risk of sharps injuries associated with the opening of traditional ampoules. Additionally, through efficient design of the manufacturing process, Advasept Lock is a cost effective solution compared to traditional glass vials.
The Advasept Lock technology is available in 1 mL, 3 mL and 5 mL container closures but may be custom designed to meet specific brand or delivery needs.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance